Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/8/2018
SIETES contiene 92466 citas

 
 
 1 a 20 de 33 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9. [Ref.ID 102647]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008;19:383-4. [Ref.ID 82775]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dawson-Hughes B, Tosteson ANA, Melton III LJ, Baim S, Favus MJ, Khosla S, Lindsay RL. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-58. [Ref.ID 82774]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Tosteson ANA, Melton III LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL. Cost-effective osteoporosis treatment thresholds: the United States perspective.. Osteoporos Int 2008;19:437-47. [Ref.ID 82773]
5.Tiene citas relacionadas Cita con resumen
Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008;371:923-31. [Ref.ID 82403]
6.Tiene citas relacionadas Cita con resumen
Mendis S, Mohan V. Non-laboratory-based prediction of cardiovascular risk. Lancet 2008;371:878-9. [Ref.ID 82393]
7.
Álvarez Cosmea A. Las tablas de riesgo cardiovascular. Una revisión crítica. Medifam 2001;11:122-39. [Ref.ID 58066]
8.Tiene citas relacionadas Cita con resumen
Anónimo. Assessing cardiovascular risk (part 2). MeReC Bulletin 2000;11:. [Ref.ID 55842]
9.Tiene citas relacionadas Cita con resumen
Anónimo. Assessing cardiovascular risk (part 1). MeReC Bulletin 2000;11:25-8. [Ref.ID 55841]
10.
Bonneux L. Cholesterol-lowering therapy for smokers and non-smokers: a life-table analysis. Lancet 2000;356:2004-6. [Ref.ID 54372]
11.Tiene citas relacionadas
Isles CG, Ritchie L D, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods. BMJ 2000;320:690-1. [Ref.ID 52051]
12.Tiene citas relacionadas Cita con resumen
13.Tiene citas relacionadas Cita con resumen
Ramachandran S, French JM, Vanderpump MPJ, Croft P, Neary R H. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 2000;320:676-7. [Ref.ID 52047]
14.Tiene citas relacionadas Cita con resumen
Wallis EJ, Ramsay L W, Haq IU, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000;320:671-6. [Ref.ID 52046]
15.Tiene citas relacionadas
Ramsay L E, Wallis EJ, Haq IU, Jackson PR, Yeo WW. Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria. BMJ 1999;318:1140-1. [Ref.ID 44435]
17.Tiene citas relacionadas
Robson J. Coronary risk assessment methods and cholesterol lowering. Authors' reply. Lancet 1999;353:1097. [Ref.ID 43589]
18.Tiene citas relacionadas
Durrington PN, Prais H, Bhatnagar D, Khan MA, France M. Coronary risk assessment methods and cholesterol lowering. Authors' reply. Lancet 1999;353:1096-7. [Ref.ID 43587]
19.Tiene citas relacionadas
Wight J. Coronary risk assessment methods and cholesterol lowering. Lancet 1999;353:1095-6. [Ref.ID 43586]
20.Tiene citas relacionadas
Tang JL, Dickinson JA, Liu JLY. Coronary risk assessment methods and cholesterol lowering. Lancet 1999;353:1095-6. [Ref.ID 43585]
Seleccionar todas
 
 1 a 20 de 33 siguiente >>